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Abstract: 
OBJECTIVES: To evaluate the effect of bakumondoto, Kampo medicine, on cough in 
patients with chronic obstructive pulmonary disease (COPD). DESIGN: A 16-week, 
randomized, open-labeled, cross-over design. SETTING: Outpatient clinics at one 
university hospital and two general hospitals in Japan from May 2007 to March 2009.  
PARTICIPANTS: Twenty-four elderly patients (14 men and 9 women aged over 65) 
with COPD. INTERVENTION: Treatment with or without bakumondoto for 8 weeks 
in a cross-over design. MEASUREMENTS: The primary outcome measurements were 
the frequency and intensity of cough assessed by a visual analogue scale (VAS) and a 
daily cough diary. Secondary outcome measurements were quality of life (QOL) 
assessed using St. George's Respiratory Questionnaire (SGRQ) and lung functions 
measured using spirometry. RESULTS: Treatment with bakumondoto significantly 
improved cough severity during the first treatment period (week 0 vs. week 8, 
p=0.004) and showed a trend to decrease during the second treatment period (week 8 
vs. week16, p=0.129) assessed by the VAS. Neither QOL nor lung function was 
affected by the treatment with bakumondoto. CONCLUSION: Bakumondoto may be 
effective in suppressing cough in elderly patients with COPD. To further confirm the 
efficacy, a larger and placebo-controlled study with objective cough assessment is 
necessary. 
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 Introduction 
Cough is a frequent symptom in patients with chronic obstructive pulmonary disease 
(COPD) and often impairs their quality of life (QOL) (Smith et al., 2006). 
Bakumondoto has been used as an antitussive agent in China for centuries, and is 
prescribed in Japan for the treatment of bronchitis and pharyngitis accompanying 
severe dry cough (Miyata, 2003). Based on these experiences, the Japanese Respiratory 
Society guidelines suggest bakumondoto as a possible antitussive agent to use for 
patients with COPD. Previous studies have demonstrated that bakumondoto was 
effective for postinfectious cough (Fujimori et al., 1998), asthmatic cough (Watanabe 
et al., 2003), and cough caused by mycoplasma bronchitis (Watanabe et al., 2008); 
however, to our knowledge, no study has been undertaken to see the effects of 
bakumondoto on cough in COPD patients. Therefore, we conducted this study to 
evaluate whether bakumondoto would demonstrate a therapeutic efficacy on cough in 
elderly patients with COPD, in particular. 
 
 
 
5
Materials and Methods 
Subjects 
Consecutive 24 elderly COPD outpatients who complained of chronic cough and met 
the criteria described below were recruited at Tadanoumi Hospital, Hiroshima 
University Hospital, and Higashi-Hiroshima Medical Center from May 2007 to March 
2009. Inclusion criteria required a baseline forced expiratory volume in 1 second 
(FEV1)/forced vital capacity (FVC) x 100 (defined as FEV1%)<70% and 
FEV1/predicted FEV1 x 100 (defined as FEV1%pred )>50%. Exclusion criteria were as 
follows: current smoker, patients who had respiratory diseases except COPD within the 
previous 4 weeks, and patients who received Kampo medicine within the previous 2 
weeks.  
The study protocol was approved by the ethics committee of Hiroshima University. All 
patients provided written informed consent, and this study was conducted in 
compliance with the ethical principles of the Helsinki Declaration. 
 
Test Drug 
Bakumondoto (Mai-men-dong-tang in Chinese) is a mixture of extracts from 6 crude 
herbs in fixed proportions (Ophiopogonis tuber: 37.0%, Pinelliae tuber: 18.5%, 
Zizyphi fructus: 11.1%, Glycyrrhizae radix: 7.85%, Ginseng radix: 7.85%, Oryzae 
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fructus: 18.5%). Each crude herb was decocted in a 10-fold weight of water for 60 min, 
filtered, and the filtrate was spray-dried to obtain an extract powder. For the analysis 
of components, 0.5 g of bakumondoto was ultrasonicated in 20 ml of methanol for 30 
min. The solution was filtered through a 0.45 μm membrane and then subjected to 
high-performance liquid chromatography (HPLC) analysis. The HPLC apparatus 
consisted of a Shimadzu LC 10A (analysis system software: CLASS-MIOA ver. 1.64, 
Tokyo, Japan) equipped with a multiple wavelength detector (UV 200-400 nm: 
Shimadzu SPD-M1OAVP, diode array detector) and an auto injector (Shimadzu 
CT0-1OAC). HPLC conditions were as follows: column, ODS (TSK-GEL 80TS, 250 
x4.6 mm i.d.,TOSOH, Tokyo, Japan); solvent, (A) 0.05 M AcONH4 (pH 3.6), (B) 
100% CH3CN; linear gradient, solvent A mixed with solvent B from 10% to 100% B in 
60 min, retention time = 20 min); temperature, 40°C ; flow rate, 1.0 ml/min. The three 
dimensional HPLC profile of bakumondoto is shown in Fig. l. The medical-grade 
extract powder of bakumondoto is commercially available in Japan and was obtained 
from Tsumura Co., Ltd. (Tokyo, Japan). Bakumondoto was administered at 3.0g of 
powder orally before each meal, three times daily (9.0g/day). 
Fig.1 
Study Design 
This study was conducted using a cross-over method, with an 8-week treatment 
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period and an 8-week non-treatment period. This study became an open-labeled study 
because it was impossible to prepare a suitable placebo due to the unique flavor and 
odor of bakumondoto. Twenty-four patients were randomized into either group A 
(n=13) or group B (n=11) by means of sealed envelopes. Patients in group A took 
bakumondoto for the first 8 weeks, and discontinued the drugs for the following 8 
weeks. In group B, the treatment was reversed in a cross-over manner. The regular 
medication for COPD in each patient was unchanged throughout the 16-week study 
period.  
 
Outcome Measurements 
The primary outcome measurement was change in severity of cough assessed by a 
visual analogue scale (VAS) and a daily cough diary. The patients subjectively 
evaluated their cough using the VAS, which consisted of a 10-cm horizontal line 
scoring between 0 (no cough) at the left end and 10 (extremely strong or frequent) at 
the right. They scored the VAS for cough frequency and for cough intensity separately. 
Therefore, the total VAS score ranged from 0 to 20 points at each evaluation. The VAS 
evaluation was performed at the start of the study and at every 4 weeks during the 
study period. 
Using the daily cough diary, the patients were also asked to daily record the severity of 
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cough based on the four categories; 0 for no cough, 1 for mild cough, 2 for strong 
cough, and 3 for extremely strong cough, in each of three time periods; morning to 
afternoon (6:00a.m. to 2:00p.m.), afternoon to night (2:00p.m. to 10:00p.m.), and 
during sleep (10:00p.m. to 6:00a.m.) during the study period. Therefore, a daily total 
score of cough severity ranged from 0 to 9 points. In advance of the start of the study, 
we had decided to use the average of the daily cough scores in the last 3 weeks of each 
8-week treatment or non-treatment period for the analysis. This is because it generally 
takes several weeks for Kampo to display its stable efficacy (Mizukami, 2009) and 
carry-over effect of bakumondoto in the non-treatment period should be excluded.  
The secondary outcome measurements were quality of life (QOL) assessed at every 4 
weeks using St. George’s Respiratory Questionnaire (SGRQ), and lung function 
measured at every 8 weeks using a spirometer (Chestgraph HI-701; CHEST M.I. Inc, 
Tokyo, Japan). 
 
Statistical Analysis 
 The data are expressed as the mean ± SD. Comparison of the VAS scores between 
pre- and post-treatment with bakumondoto was analyzed by the Wilcoxon signed-rank 
test. The two groups’ data were analyzed by the Wilcoxon rank-sum test comparing the 
changes of the average scores in the cough diaries from the first 8-week period to the 
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second. A p value of <0.05 was considered to be significant. Analyses were performed 
using SAS, version 9.13 (SAS Institute, Inc., Japan). 
 
Safety 
Throughout the 16-week study period, adverse events for which a causal relationship 
with bakumondoto could not be ruled out were noted in two patients. In these two 
patients, alkaline phosphatase levels slightly increased after eight weeks of the 
treatment with bakumondoto. No other adverse events were observed.  
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Results 
Characteristics of the Study Subjects 
One patient of the A group was excluded from the analysis because no data on cough 
severity was recorded. The characteristics of the remaining 23 patients who enrolled in 
this study are summarized in Table 1. There were no significant differences in age, sex 
ratio, VAS score, FEV1%, and FEV1%pred at baseline between the two groups. Two 
patients from each group refused to take bakumondoto in the middle of the treatment 
period due to difficulty of swallowing the medicine. The part of halfway data until 
these patients stopped taking bakumondoto was included in the analysis. The 
remaining 10 patients in group A and 9 patients in group B completed the 16-week 
study. 
Table1 
Outcomes 
As shown in Fig. 2A, VAS scores in group A significantly decreased during the 
treatment period (week 0 vs. week 8, p=0.005). VAS scores in group B also showed a 
trend to decrease during the treatment, however this change did not reach statistical 
significance (week 8 vs. week16, p=0.129). Then, the VAS scores for cough intensity 
and frequency were analyzed separately. As shown in Fig.2B, the VAS scores for 
cough intensity in each of groups A and B during the treatment period tended to 
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improve, however these changes did not reach statistical significance (group A, week 0 
vs. week 8, p=0.055; group B, week 8 vs. week 16, p=0.387). The VAS score for cough 
frequency during the treatment period significantly improved in group A (Fig. 2C; 
week 0 vs. week 4, p=0.007; week 0 vs. week 8, p=0.001). It also showed a trend to 
decrease during the treatment period in group B, however this change did not reach 
statistical significance (Fig.2C; week 8 vs. week 16, p=0.055). 
Fig.2ABC 
We next examined the changes in the average scores of cough severity recorded in the 
daily cough diary. The average score for cough severity in group A changed from 2.90 
at the treatment period to 3.88 at the non-treatment period. Similarly, the average score 
for cough severity in group B changed from 3.83 at the non-treatment period to 3.12 at 
the treatment period. As shown in Fig. 3, the lines connecting the average scores 
during 6 to 8 weeks and 14 to 16 weeks of the study period in the two groups crossed 
and the changes from the former to the latter time points significantly differed between 
groups A and B (group A, 0.98 ± 1.08 vs. group B, –0.71 ± 1.04; p=0.006).  
The SGRQ scores and FEV1% did not significantly change before and after the 
treatment with bakumondoto in each group (data not shown). No serious adverse event 
was observed. 
Fig.3 
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Discussion 
Cough is one of the most frequent symptoms reported by patients with COPD 
(Rennard et al., 2002) and is known to impair QOL (Miravitlles et al., 2007). 
Successful treatment of cough in COPD patients should have great clinical 
significance; however, effective therapy has not yet been identified (Smith et al., 2004). 
A recent randomized, placebo-controlled trial has shown that codeine, a common 
antitussive agent, was not effective in the management of cough in COPD patients 
(Smith et al., 2006). In this study, interestingly, codeine also failed to significantly 
improve subjective cough severity from the baseline. In another clinical trial, 
theophylline and long acting -agonist did not show a statistically significant 
improvement in subjective measurements of cough from the baseline (Nishimura et al., 
1995; Aalbers et al., 2002). To our best knowledge, there is no treatment that has 
improved subjective cough severity in patients with COPD. In the present study, 
bakumondoto was found to significantly improve cough severity subjectively assessed 
using daily cough diary and the VAS without any serious adverse events. However, this 
statistically significant improvement in cough severity assessed by VAS was observed 
only in group A but not in group B. We believe that this is caused by the lower average 
VAS scores in group B (7.9 ± 3.0) compared with those in group A (10.2 ± 4.5) at 
baseline. Another possible reason may be simply the too small sample size to detect 
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statistical significance. 
There are a couple of studies that suggest the mechanisms of bakumondoto to serve 
as an antitussive agent. Using a guinea-pig model of long-term exposure to 
cigarette-smoke, Kamei et al. showed that bakumondoto had an effect to reduce cough 
sensitivity (Smith et al., 2005). They also found that bakumondoto decreased nitric 
oxide (NO) metabolites in bronchoalveolar lavage fluid, suggesting that the antitussive 
effect of bakumondoto might be mediated by the inhibition of synthesis or release of 
NO. In fact, a high level expression of inducible NO synthase (iNOS) in sputum 
macrophages, alveolar walls, small airway epithelium are observed in COPD patients 
(Ichinose et al., 2000; Paska et al., 2002) and a recent cross-sectional study has shown 
that there was a significant elevation in fraction of exhaled NO in patients with stable 
COPD (Beg et al., 2005). Other studies reported by Aizawa et al. (1999, 2003) 
demonstrated that bakumondoto inhibited airway hyperresponsiveness induced by 
ozone in guinea pigs through inhibiting the release of acetylcholine from vagal nerve 
terminals. Because the dysregulation of vagal nervous system leading to decreased 
cough threshold is suggested as a mechanism for cough in COPD patients (Undem et 
al., 2005), bakumondoto may have a beneficial effect on cough induced through this 
process. 
 Based on these suggested mechanisms for cough, bakumondoto can be regarded as 
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a peripherally acting antitussive drug. Centrally acting drugs, such as codeine and 
dextromethorphan, are currently most used antitussives, however, they are often 
associated with unpleasant or intolerable side effects, including sedation, nausea, and 
constipation. To avoid these side effects of centrally acting drugs, bakumondoto may 
be a more suitable antitussive drug for cough in elderly COPD patients. In addition, 
through animal or in vitro experiments, Miyata et al. reported that bakumondoto had 
various pharmacological actions, such as anti-inflammatory, anti-allergic, 
immunomodulatory, secretory-modulating, and metabolic regulatory effects (Miyata, 
2004; Miyata et al., 2007). These wide-ranging effects of bakumondoto may be 
suitable for the treatment of patients with COPD, which is now recognized as a 
systemic disease. 
Although it subjectively improved cough in COPD patients, bakumondoto did not 
affect QOL assessed by SGRQ. Because the questions regarding cough occupy only a 
small portion in SGRQ, this result indicates that respiratory symptoms, such as 
breathlessness or wheezing, other than cough did not change by the treatment with 
bakumondoto. If cough-specific health-related quality of life questionnaires (e.g. the 
Cough Quality of Life Questionnaire and the Leicester Cough Questionnaire) were 
used instead of SGRQ, the outcomes might be different.  
Besides the small sample size, we are aware that there are a couple of limitations in 
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this study. Due to the unique flavor and odor of bakumondoto, placebo could not be 
prepared. The usage of other Kampo medicine as placebo was considered, however, we 
judged that this substitution would cause an ethical problem. Therefore, this study was 
conducted as an open-labeled one without placebo. In addition, the outcome 
measurements did not include objective assessment of cough such as measurement of 
cough reflex sensitivity. Further analysis to objectively assess the efficacy of 
bakumondoto as an antitussive agent is definitely needed. 
In conclusion, this study demonstrates that the multiherb Kampo Medicine 
bakumondoto may be effective in subjectively suppressing cough in COPD patients 
without impairing their QOL or affecting lung function while general medical 
treatment for COPD was being undertaken. Bakumondoto did not cause any adverse 
events even in elderly patients. To our best knowledge, this is the first study that 
demonstrated the statistically significant improvement in cough severity assessed by 
subjective measurements. To further confirm the efficacy of bakumondoto as an 
antitussive agent in COPD, larger and placebo-controlled study with objective cough 
assessment would be necessary. 
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Figure legends. 
Fig. 1. The three-dimensional HPLC profile of bakumondoto. 
 
Fig. 2. Changes in scores of cough severity assessed by visual analog scale. Each value 
is presented as change from the baseline score, with the median +/- standard deviation 
(SD). Period of treatment with bakumondoto: Group A, 0 to 8 weeks; Group B, 8 to 16 
weeks. (A) Summation of scores for cough intensity and frequency. Group A: 0 week 
vs. 8 week; **P=0.004. Group B: 8 week vs. 16 week; P=0.129. (B) Scores for cough 
intensity. Group A: 0 week vs. 8 week; P=0.055. Group B: 8 week vs. 16 week; 
P=0.387.  (C) Scores for cough frequency. Group A: 0 week vs. 4 week; **P=0.007, 8 
week; ***P=0.001. Group B: 8 week vs. 16 week; P=0.054.  
 
Fig. 3. Changes in scores of cough severity assessed using daily cough diary. Each 
value is the average of the daily cough scores in the last 3 weeks of each 8-week 
treatment or non-treatment period, representing the mean +/- standard deviation (SD). 
Changes of cough diary score are 0.98+/-1.08 in Group A and -0.71+/-1.04 in Group B. 
Group A vs. Group B; **P=0.006. 
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0.164 7.9+/-3.010.8+/-4.8Total Cough VAS 
0.164 85.8+/-23.471.9+/-21.2FEV1%pred (%)  
0.202 66.8+/-8.5 61.9+/-9.3 FEV1/ FVC (%)  
0.381 79.2+/-2.676.2+/-8.5Age (year), mean +/- S.D. 
-  6/5 9/4 Gender (M/F)
-  11 13n 
Wilcoxon test
Group B 
 
（treatment 
 
 week 8-16 ） 
Group A 
 
（treatment 
  
week 0-8 ） 
Demographic data 
M = male; F = female; SD = standard deviation; FEV1 = forced expiratory 
volume in 1 second; FVC = forced vital capacity; VAS = visual analogue scale
Table 1. Characteristics of the Studied Subjects.



